136 related articles for article (PubMed ID: 38157649)
1. Feasibility of S-1 adjuvant chemotherapy after major hepatectomy for biliary tract cancers: An exploratory subset analysis of JCOG1202.
Kobayashi S; Nakachi K; Ikeda M; Konishi M; Ogawa G; Sugiura T; Yanagimoto H; Morinaga S; Wada H; Shimada K; Takahashi Y; Nakagohri T; Kamata K; Shimizu Y; Ajiki T; Hirano S; Gotohda N; Ueno M; Okusaka T; Furuse J
Eur J Surg Oncol; 2024 Feb; 50(2):107324. PubMed ID: 38157649
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Feasibility of Adjuvant Gemcitabine Plus Cisplatin Chemotherapy After Major Hepatectomy for Biliary Tract Cancer.
Mori S; Aoki T; Shiraki T; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Sakuraoka Y; Iso Y; Kubota K
Anticancer Res; 2021 Oct; 41(10):5231-5240. PubMed ID: 34593476
[TBL] [Abstract][Full Text] [Related]
3. Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer.
Nakachi K; Konishi M; Ikeda M; Shimada K; Okusaka T; Saiura A; Ishii H; Sugiyama M; Furuse J; Sakamoto H; Shimamura T; Ohta T
Int J Clin Oncol; 2018 Oct; 23(5):894-899. PubMed ID: 29705976
[TBL] [Abstract][Full Text] [Related]
4. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202).
Yanagimoto H; Toyokawa H; Sakai D; Wada H; Satoi S; Yamamoto T; Nagano H; Toyoda M; Ajiki T; Satake H; Tsuji A; Miyamoto A; Tsujie M; Takemura S; Yanagihara K; Ioka T
Cancer Chemother Pharmacol; 2018 Mar; 81(3):461-468. PubMed ID: 29305639
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Nakachi K; Ikeda M; Konishi M; Nomura S; Katayama H; Kataoka T; Todaka A; Yanagimoto H; Morinaga S; Kobayashi S; Shimada K; Takahashi Y; Nakagohri T; Gotoh K; Kamata K; Shimizu Y; Ueno M; Ishii H; Okusaka T; Furuse J;
Lancet; 2023 Jan; 401(10372):195-203. PubMed ID: 36681415
[TBL] [Abstract][Full Text] [Related]
6. Difficulty of adjuvant chemotherapy administration in patients with biliary tract cancer.
Sumiyoshi T; Uemura K; Shintakuya R; Okada K; Baba K; Harada T; Serikawa M; Ishii Y; Nakamura S; Arihiro K; Murakami Y; Takahashi S
Langenbecks Arch Surg; 2023 Nov; 408(1):445. PubMed ID: 37999810
[TBL] [Abstract][Full Text] [Related]
7. Completion of adjuvant S-1 chemotherapy after surgical resection for biliary tract cancer: A single center experience.
Iwaki K; Yoh T; Nishino H; Nishio T; Koyama Y; Ogiso S; Ishii T; Kanai M; Hatano E
Asian J Surg; 2024 Mar; 47(3):1383-1388. PubMed ID: 38160154
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study.
Kobayashi S; Nagano H; Sakai D; Eguchi H; Hatano E; Kanai M; Seo S; Taura K; Fujiwara Y; Ajiki T; Takemura S; Kubo S; Yanagimoto H; Toyokawa H; Tsuji A; Terajima H; Morita S; Ioka T
Cancer Chemother Pharmacol; 2014 Oct; 74(4):699-709. PubMed ID: 25074036
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101).
Fujiwara Y; Kobayashi S; Nagano H; Kanai M; Hatano E; Toyoda M; Ajiki T; Takashima Y; Yoshimura K; Hamada A; Minami H; Ioka T
PLoS One; 2015; 10(12):e0143072. PubMed ID: 26633034
[TBL] [Abstract][Full Text] [Related]
10. A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group.
Kobayashi S; Nagano H; Tomokuni A; Gotoh K; Sakai D; Hatano E; Seo S; Terajima H; Uchida Y; Ajiki T; Satake H; Kamei K; Tohyama T; Hirose T; Ikai I; Morita S; Ioka T;
Ann Surg; 2019 Aug; 270(2):230-237. PubMed ID: 30339627
[TBL] [Abstract][Full Text] [Related]
11. A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT).
Nakachi K; Konishi M; Ikeda M; Mizusawa J; Eba J; Okusaka T; Ishii H; Fukuda H; Furuse J;
Jpn J Clin Oncol; 2018 Apr; 48(4):392-395. PubMed ID: 29462482
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of omega-3 fatty acid administration on completion rate of adjuvant chemotherapy for biliary tract cancer: study protocol for a single-centre, open-label, single-arm, historically controlled study.
Ueno K; Ajiki T; Tsugawa D; Akita M; Hashimoto Y; Awazu M; Mukubo H; Komatsu S; Kuramitsu K; Terai S; Tanaka M; Toyama H; Kido M; Fukumoto T
BMJ Open; 2019 Aug; 9(8):e029915. PubMed ID: 31401605
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer.
Kainuma O; Miura F; Furukawa D; Yamamoto H; Cho A; Sano K; Nakagohri T; Asano T
J Hepatobiliary Pancreat Sci; 2015 Nov; 22(11):789-94. PubMed ID: 26234468
[TBL] [Abstract][Full Text] [Related]
14. A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer.
Yamanaka K; Hatano E; Kanai M; Tanaka S; Yamamoto K; Narita M; Nagata H; Ishii T; Machimoto T; Taura K; Uemoto S
Int J Clin Oncol; 2014; 19(3):485-9. PubMed ID: 23765238
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection.
Kim YS; Jeong CY; Song HN; Kim TH; Kim HJ; Lee YJ; Hong SC
Chin J Cancer; 2017 Jan; 36(1):9. PubMed ID: 28086990
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 Trial of Adjuvant Chemotherapy With S - 1 for Node-Positive Biliary Tract Cancer (N-SOG 09).
Seita K; Ebata T; Mizuno T; Maeda A; Yamaguchi R; Kurumiya Y; Sakamoto E; Hiramatsu K; Ando M; Nagino M
Ann Surg Oncol; 2020 Jul; 27(7):2348-2356. PubMed ID: 32180066
[TBL] [Abstract][Full Text] [Related]
18. Effect of biliary drainage on chemotherapy in patients with biliary tract cancer: an exploratory analysis of the BT22 study.
Fukutomi A; Furuse J; Okusaka T; Miyazaki M; Taketsuna M; Koshiji M; Nimura Y
HPB (Oxford); 2012 Apr; 14(4):221-7. PubMed ID: 22404259
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.
Edeline J; Benabdelghani M; Bertaut A; Watelet J; Hammel P; Joly JP; Boudjema K; Fartoux L; Bouhier-Leporrier K; Jouve JL; Faroux R; Guerin-Meyer V; Kurtz JE; Assénat E; Seitz JF; Baumgaertner I; Tougeron D; de la Fouchardière C; Lombard-Bohas C; Boucher E; Stanbury T; Louvet C; Malka D; Phelip JM
J Clin Oncol; 2019 Mar; 37(8):658-667. PubMed ID: 30707660
[TBL] [Abstract][Full Text] [Related]
20. A Multicenter Survey on Eligibility for a Randomized Phase III Trial of Adjuvant Chemotherapy for Resected Biliary Tract Cancer (JCOG1202, ASCOT).
Kobayashi S; Ikeda M; Nakachi K; Ueno M; Okusaka T; Todaka A; Satoi S; Tomokuni A; Konishi M; Furuse J
Ann Surg Oncol; 2023 Nov; 30(12):7331-7337. PubMed ID: 37450093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
